Towards Healthcare
TD Vaccine Market Size Soars USD 6.52 Billion in 2025

TD Vaccine Market Driven by Tdap Demand, AI-Based R&D, and Gavi Support

According to forecasts, the global TD vaccine market will grow from USD 6.17 billion in 2024 to USD 10.68 billion by 2034, with an expected CAGR of 5.64%. Increasing global health programs and the development of combination vaccines are fueling demand for the Td vaccine around the globe. However, the Asia Pacific dominated market due to high birth cohorts, routine immunization programs in India, Bangladesh, Indonesia, and WHO-supported initiatives. 

  • Insight Code: 5844
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: July 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Rohan Patil is a seasoned market research professional with over 5 years of focused experience in the healthcare sector, bringing deep domain expertise, strategic foresight, and analytical precision to every project he undertakes.

He began his journey with Precedence Research, where he played a pivotal role in developing high-impact healthcare market reports. Today, Rohan leads research initiatives at Towards Healthcare, while also contributing to Statifacts, where he supports cross-industry analysis and data-driven storytelling.

Rohan’s core strengths lie in trend analysis and emerging technologies, regulatory monitoring and thought leadership through high-quality report writing. He excels at identifying future-ready opportunities and translating complex data into strategic recommendations. His work spans pharmaceuticals, biotechnology, medical devices, and digital health, assessing everything from market potential and competitive positioning to customer needs and regulatory shifts.

A trusted advisor and a relentless innovator, Rohan continues to push the boundaries of traditional market research, merging scientific rigor with commercial insight to stay ahead in a fast-evolving healthcare landscape.

FAQ's

The TD vaccine market is projected to reach USD 10.68 billion by 2034, growing at a CAGR of 5.64% from 2024 to 2034.

Asia Pacific is currently leading the TD vaccine market due to large birth cohorts, routine immunization programs in India, Bangladesh, Indonesia, and WHO-supported initiatives.

The TD vaccine market includes six segments, such as by product type, by age group, by end user, by formulation, by distribution channel, and by region, etc.

Some key players include Pfizer, Bharat Biotech International Ltd., Panacea Biotec Ltd, Sanofi, and GlaxoSmithKline.

Key trends include rising demand for Tdap vaccines, growth in programs related to awareness about risks of Tetanus and diphtheria and vaccination importance, and innovation in clinical trials, combination vaccines.

Td is used in tetanus and diphtheria, whereas the Tdap vaccine is used against pertussis (whooping cough) in addition to tetanus and diphtheria. 

Common side effects of the Td vaccine include pain, redness, or swelling at the injection site, mild fever, headache, tiredness, and sometimes nausea, vomiting, diarrhea, or stomach ache. 

The World Health Organization (WHO) guidelines a 6-dose schedule of tetanus toxoid-containing vaccines (TTCV) for lifetime protection. 

WHO, UNICEF, NIH.GOV, CDC.GOV, NHS, GOV.UK, PIB.GOV, NHM.GOV, HHS.GOV, MEDLINEPLUS.GOV